Reservoir Neuroscience, Inc

Santen is a wholly owned subsidiary of Santen Pharmaceutical. Located in Northern California s Napa Valley, the United States office is comprised of health care professionals with its senior management team totaling more than 20 years of industry experience, knowledge and expertise based exclusively in the ophthalmic field. In early 2004, Santen entered into a partnership agreement with VISTAKON Pharmaceuticals, granting VISTAKON the exclusive U.S. distribution rights to the Santen ophthalmic products QUIXIN 0.5%, BETIMOL 0.25% and 0.5%, and ALAMAST 0.1%, as well as its newest product IQUIX 1.5%, which gained FDA approval in March 2004. Santen is also actively pursuing technological alliances with a number of pharmaceutical companies and research institutes and has investments in an intraocular lens company. Santen opened its doors in the San Francisco Bay Area in 1993.

Kyverna Therapeutics, Inc, based in Emeryville, CA, is a patient-centered, clinical-stage biopharmaceutical company specializing in developing cell therapies for autoimmune diseases. The company's mission is to provide life-changing medicines for patients affected by autoimmune disorders by harnessing the curative potential of cell therapy. Kyverna is at the forefront of a new era in CAR T-cell therapy, pioneering a durable disease-clearing approach that targets deep B cell depletion, immune system reset, and long-term remission in autoimmune conditions. The company's pipeline includes next-generation CAR T-cell therapies in autologous and allogeneic formats, tailored to combat B cell-driven autoimmune diseases like lupus nephritis, multiple sclerosis, myasthenia gravis, stiff person syndrome, and systemic sclerosis. With a patient-centric focus, Kyverna is actively conducting clinical trials in multiple autoimmune diseases globally, offering a promising avenue for patients seeking innovative treatment options beyond conventional therapies. By leveraging the success of CAR T-cell therapies in hematological malignancies, Kyverna aims to deliver therapeutic benefits that can potentially change the landscape of autoimmune disease treatment. Generated from the website content

Founded in 2006, Zogenix Inc. is a privately held, specialty pharmaceutical company. It develops and commercializes differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. Zogenix Inc has received approval from the Food and Drug Administration (FDA) for SUMAVEL DosePro (sumatriptan injection) needle-free delivery system, which is a drug-device combination that enables needle-free delivery of subcutaneous sumatriptan for the treatment of acute migraine and cluster headache. The company s other product, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. Zogenix Inc. is supported by several investors, including Abingworth Management Ltd., Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partner and others.